ライフサイエンスコーパス: genitourinary

1 , GI (27%), gynecologic (17%), breast (11%), genitourinary (10%), or other (6%) cancer joined this pr

2 These were followed by genitourinary (28%), abdominal (14%) and chest and breas

3 Cardio-Circulatory, Mental, Respiratory and Genitourinary (28.8%).

4 ian age: 55 years; most frequent tumor site: genitourinary (45%); palliative treatment: n = 41 (34%)]

5 tion were related to cardiovascular (31.8%), genitourinary (8.7%), digestive (8.3%), endocrine, nutri

6 Diseases of digestive (110 922; 16%), genitourinary (82 505; 12%), and musculoskeletal system

7 %-95.0%) and 90% (80.0%-90.0%); and (4) mild genitourinary, 90% (81.8%-91.3%) and 80% (71.8%-90%).

8 9% (80%-95%) and 80% (70%-89.5%); (3) severe genitourinary, 91% (87.3%-95.0%) and 90% (80.0%-90.0%);

9 a, structural CNS malformations, ataxia, and genitourinary abnormalities.

10 gic anomalies, congenital heart defects, and genitourinary abnormalities.

11 does not increase either gastrointestinal or genitourinary acute toxicity.

12 There was no difference in related genitourinary adverse events between treatment arms comp

13 roportion of women who had grade 2 or higher genitourinary adverse events judged related to study pro

14 r 8.2 weeks, although an increase in late GI/genitourinary adverse events was observed in patients tr

15 Late grade 2 and 3 GI and genitourinary adverse events were increased (HR, 1.31 to

16 istically significant differences in related genitourinary AEs or grade >=2 AEs observed between arms

17 Acute genitourinary and gastrointestinal toxicity as defined b

18 ack and limbs can be affected as well as the genitourinary and gastrointestinal tracts.

19 e detected between arms for grade >/= 3 late genitourinary and GI toxicity.

20 r probability of experiencing 30- and 90-day genitourinary and miscellaneous medical complications (a

21 idity and mortality, increased rates of both genitourinary and non-genitourinary malignancy, and grea

22 whole-gland therapy can lead to significant genitourinary and rectal side-effects for men with local

23 ied by infection source (undifferentiated vs genitourinary) and severity (mild vs severe) denoted by

24 nts (70% gastrointestinal, 21% epistaxis, 3% genitourinary, and 6% intracranial).

25 critical roles in the immune, reproductive, genitourinary, and auditory systems.

26 the mucosal epithelia of human respiratory, genitourinary, and digestive tracts.

27 luded cardiac, respiratory, vascular, wound, genitourinary, and miscellaneous surgical and medical co

28 autonomic cardiovascular, gastrointestinal, genitourinary, and sudomotor symptoms in all subjects.

29 or suppressor gene WT1 results in a range of genitourinary anomalies in humans, including 46,XY gonad

30 n of newborn Noggin-/- male fetuses revealed genitourinary anomalies including cryptorchidism, incomp

31 4%) anomalies; interestingly, this group had genitourinary anomalies more frequently (47%) compared t

32 14.1), result in the Wilms' tumor, aniridia, genitourinary anomalies, and mental retardation (WAGR) s

33 of WAGR syndrome for Wilm's tumor, aniridia, genitourinary anomalies, and mental retardation) is a ra

34 Unlike WAGR (Wilms tumor, aniridia, genitourinary anomalies, and mental retardation) syndrom

35 GR syndrome (the clinical triad of aniridia, genitourinary anomalies, and mental retardation, a subgr

36 led to aniridia, polycystic kidney disease, genitourinary anomalies, and mental retardation, similar

37 onosis and the absence of kidneys with other genitourinary anomalies, expression of the Ret(H)(2B) tr

38 rt first metacarpals, facial dysmorphism and genitourinary anomalies.

39 powerful tool for the diagnosis of pediatric genitourinary anomalies.

40 ed to be useful in the evaluation of complex genitourinary anomalies.

41 eal dysfunction; cardiac, ophthalmologic and genitourinary anomalies; hirsutism; and characteristic f

42 ad significantly diminished weights of their genitourinary apparatuses and dorsolateral and ventral p

43 s been directly implicated in numerous other genitourinary as well as extragenitourinary tract pathol

44 atment-related factors in addition to GI and genitourinary baseline function, with higher scores repr

45 s well as emerging translational evidence of genitourinary birth defects and their impact on male inf

46 ion of the reproductive tract and results in genitourinary birth defects in humans.

47 site, retroperitoneal, gastrointestinal, or genitourinary bleeding; intracranial hemorrhage; cardiac

48 0.0), colorectal cancer (7.0%, 6.1-8.0), and genitourinary cancer (5.6%, 4.5-6.7).

49 CI], 1.15-2.02; P = 0.004), particularly for genitourinary cancer (adjusted HR, 1.79; 95% CI, 1.03-3.

50 Urine from 91 patients without genitourinary cancer and serum from 30 age-matched nonca

51 vant chemotherapies to kill gastrointestinal/genitourinary cancer cells.

52 inicians (physicians and nurses) in lung and genitourinary cancer clinics in the Memorial Sloan-Kette

53 from 91 control subjects without evidence of genitourinary cancer revealed no methylation of the MGMT

54 les from the 91 controls without evidence of genitourinary cancer revealed no methylation of the p16,

55 st cancer, sarcoma, gastrointestinal cancer, genitourinary cancer, gynaecological cancer, thoracic ca

56 ly member D-dopachrome tautomerase (DDT)) in genitourinary cancers and how it can be therapeutically

57 Genitourinary cancers are the second most common tumors

58 A pathologist with expertise in genitourinary cancers assigned Gleason scores to the pro

59 cular biologic events involved in children's genitourinary cancers continue to advance treatment.

60 Genitourinary cancers encompass some of the most common

61 f Hodgkin lymphoma, acute myeloid leukaemia, genitourinary cancers other than bladder cancer, non-Hod

62 culture and in preclinical animal models of genitourinary cancers reduces the phenotypic hallmarks o

63 are chemotherapy agents for gastrointestinal/genitourinary cancers represents a novel modality.

64 n (LMWH) in patients with GI and potentially genitourinary cancers.

65 carcinoma (CC-RCC) is the most lethal of all genitourinary cancers.

66 ble for cervical, oropharyngeal, and various genitourinary cancers.

67 increasing case detection by 44.3% from 300 genitourinary cases to 433 total cases, ranging from 21.

68 ared between rectal-only chlamydia cases and genitourinary cases using chi(2) or Fisher exact test, M

69 Congenital malformations of anorectal and genitourinary (collectively, anogenital) organs occur at

70 cognitive), somatic (muscular), respiratory, genitourinary complaints; and depressed behavior were mo

71 RRP was associated with an increased risk of genitourinary complications (4.7% vs 2.1%; P = .001) and

72 tional cancer therapies but experienced more genitourinary complications, incontinence, and erectile

73 ons (46.0%), gynecologic conditions (21.6%), genitourinary conditions (16.9%), and hepatopancreaticob

74 ever (n = 281; 13%), and gastrointestinal or genitourinary conditions (n = 268; 12%), among others.

75 Despite the fact that genitourinary defects are among the most common birth de

76 Genitourinary defects resulting from disruption of AR ac

77 nt for the association between anorectal and genitourinary defects.

78 atal growth; variable skeletal, cardiac, and genitourinary defects; and death in infancy in one indiv

79 utely necessary for Sprouty1 function during genitourinary development in mice.

80 The GenitoUrinary Development Molecular Anatomy Project (GUD

81 Presented here is a brief overview of the Genitourinary Developmental Molecular Anatomy Project ef

82 There are three components to the Genitourinary Developmental Molecular Anatomy Project GU

83 but other causes contributed, particularly, genitourinary, digestive, and endocrine, nutritional, an

84 ory disease (RR = 1.19, 95% CI: 1.02, 1.39), genitourinary disease (RR = 1.39, 95% CI: 1.07, 1.82), a

85 d specificity in patients with non-malignant genitourinary disease or other disorders.

86 those with other malignant and non-malignant genitourinary disease ranged from 86% to 100%.

87 viduals, and 138 patients with non-malignant genitourinary disease.

88 nd patients with malignant and non-malignant genitourinary disease.

89 and benign prostatic hyperplasia are common genitourinary diseases in aging men.

90 sensory loss, musculoskeletal disorders, and genitourinary diseases).

91 etal and connective tissue diseases; and (7) genitourinary diseases.

92 types involved cardiovascular, obesity, and genitourinary diseases.

93 1; surgical 2.62, 1.69-4.06, p<0.0001), or a genitourinary disorder (2.19, 1.43-3.36, p=0.0003).

94 high white blood cell count (aOR 1.08), and genitourinary disorder (aOR 1.08).

95 ental genetic findings related to kidney and genitourinary disorders will require stringent curation

96 5 genes associated with Mendelian kidney and genitourinary disorders.

97 given the prevalence of monogenic kidney and genitourinary disorders.

98 ious complications or deleterious changes in genitourinary function.

99 A basic assessment of facial, skeletal, genitourinary, gastrointestinal and integumentary abnorm

100 Rates of late genitourinary (GU) and GI toxicity were assessed using t

101 grade 2 and two patients (0.6%) had grade 3 genitourinary (GU) baseline symptoms.

102 ion hazard ratios (sHRs) by comparing GI and genitourinary (GU) complications for PPLN-IMRT versus PO

103 resent study was to compare the incidence of genitourinary (GU) dysfunction after elective laparoscop

104 astatic urothelial carcinoma (mUC) and other genitourinary (GU) malignances.

105 f UTI and STI in adult women presenting with genitourinary (GU) symptoms or diagnosed with GU infecti

106 or lower tract (reproductive organs) of the genitourinary (GU) system are fundamentally linked by th

107 CS-sorted components of the developing mouse genitourinary (GU) system.

108 Gastrointestinal (GI) and genitourinary (GU) toxicities were reviewed for each of

109 ity (DLT) was defined as grade 3 or worse GI/genitourinary (GU) toxicity by Common Terminology Criter

110 s; we used a random effects model to compare genitourinary (GU), GI, and other toxicity between match

111 recently diagnosed breast, gastrointestinal, genitourinary, gynecological, head and neck, lung, lymph

112 al atresia, retarded growth and development, genitourinary hypoplasia and ear abnormalities.

113 with urolithiasis lends support for routine genitourinary imaging in order to identify and treat tho

114 ; and respiratory, nonspecific symptoms, and genitourinary in non-ESRD.

115 iomyopathy or other cardiac disease (18.3%), genitourinary infection (11.5%), complications from ecto

116 y infection (OR = 1.00, 95% CI: 0.99, 1.01), genitourinary infection (OR = 1.01, 95% CI: 0.99, 1.02),

117 Genitourinary infections (GUIs) have been associated wit

118 These results suggest that early genitourinary infections may contribute to later develop

119 ation describes a long list of side effects: genitourinary infections, ketoacidosis, bone fractures,

120 Gestational genitourinary infections, which have been associated wit

121 s over the past 3 years in the management of genitourinary injuries, surgical wounds, and complicatio

122 For men with significant genitourinary injury, penile transplantation is being co

123 icities between the 2 groups (late-grade 3-4 genitourinary <3%; gastrointestinal <4%).

124 ul human pathogen associated with a range of genitourinary maladies.

125 S) and WAGR syndrome (Wilms tumor, aniridia, genitourinary malformations, and mental retardation).

126 Patients with Wilms' tumor, aniridia, major genitourinary malformations, and mental retardation, the

127 ial defects, clavicular hypoplasia, anal and genitourinary malformations, and skin eruption.

128 nital phase causes coordinated anorectal and genitourinary malformations, whereas inactivation during

129 Bladder cancer is one of the most common genitourinary malignancies and is a potentially life-thr

130 The major genitourinary malignancies and their management will be

131 ggable fusion events have been recognized in genitourinary malignancies, leading to the activation of

132 In genitourinary malignancies, rearrangements involving the

133 States in 2005, making it the most lethal of genitourinary malignancies.

134 ancer continues to be one of the most common genitourinary malignancies.

135 ve bladder carcinomas (MIBCs) are aggressive genitourinary malignancies.

136 e-matched individuals without any history of genitourinary malignancy as controls.

137 ncreased rates of both genitourinary and non-genitourinary malignancy, and greater risks of systemic

138 ggest that it is a pro-tumorigenic factor in genitourinary malignancy.

139 d on the basis of the results of a survey of genitourinary medical oncologists.

140 Diagnoses of genital warts (GW) in genitourinary medicine (GUM) clinics have been increasin

141 ess of offering vaccination to MSM who visit genitourinary medicine (GUM) clinics.

142 llected by a cross-sectional survey of 2,203 genitourinary medicine clinic patients in England in 200

143 recruited 82 participants from an outpatient genitourinary medicine clinic.

144 ing clinical trial was conducted in European genitourinary medicine clinics between December 20, 2001

145 Programme (GRASP) for patients attending 26 genitourinary medicine clinics in England and Wales betw

146 Of 197 eligible patients from genitourinary medicine clinics, 161 accessed results onl

147 were untreated patients with chlamydia from genitourinary medicine clinics, untreated patients with

148 xually transmitted infection, the ability of genitourinary medicine services to provide appropriate a

149 They define a core genitourinary microbiome for older women with many herit

150 re a part of the normal gastrointestinal and genitourinary microbiota and have rarely been reported t

151 In the genitourinary MR imaging radiologist group of patients,

152 Readers of MR images were classified into genitourinary MR imaging radiologists (n = 4) and genera

153 rve with endorectal MR images interpreted by genitourinary MR imaging radiologists (P =.019 and.31, r

154 ly found in the oral cavity, intestinal, and genitourinary mucosa as part of the normal microbiota.

155 skin cancer (n = 278), digestive (n = 105), genitourinary (n = 100), breast (n = 97), and bone (n =

156 at older than 40 years was for digestive and genitourinary neoplasms.

157 rwent inpatient general, vascular, thoracic, genitourinary, neurosurgical, orthopedic, or spine surge

158 tain features that promote adaptation to the genitourinary niche, making them gonococcus-like and dis

159 Patients with genitourinary nonbladder prostate tumors had the most fa

160 The therapeutic armamentarium available to genitourinary oncologists continues to grow, but much wo

161 No significant differences in acute genitourinary or gastrointestinal toxicity were observed

162 rences in rectal or bladder dose or in acute genitourinary or gastrointestinal toxicity.

163 rences in rectal or bladder dose or in acute genitourinary or gastrointestinal toxicity.

164 s not recommended for patients who undergo a genitourinary or gastrointestinal tract procedure.

165 eceiving chemotherapy for lung, gynecologic, genitourinary, or breast cancer at a tertiary cancer cen

166 from patients with breast, lung, colorectal, genitourinary, or gynaecological cancer who had particip

167 e the role of various signaling molecules in genitourinary organogenesis.

168 ), breast (7.6%), gynecologic organs (7.1%), genitourinary organs (4.2%), esophagus (3.6%), skin (mel

169 malies that affect sexual differentiation of genitourinary organs and secondary sex characters.

170 gle-organ vasculitis affecting abdominal and genitourinary organs, breast and aorta have been reporte

171 uired for normal patterning of digestive and genitourinary organs.

172 important role in proper development of the genitourinary organs.

173 ascular p < 0.01; gastrointestinal p < 0.01; genitourinary p < 0.01) and autonomic function tests (p

174 A genitourinary pathologist blinded to MP MR findings outl

175 tudied, and the histology was confirmed by a genitourinary pathologist.

176 s, including depression, constipation, pain, genitourinary problems, and sleep disorders, can be impr

177 .8%), and slightly more men had pretreatment genitourinary procedures (24.2% v 21.2%).

178 ion of ECE when MR images are interpreted by genitourinary radiologists experienced with MR imaging o

179 ry analysis was performed by two experienced genitourinary radiologists for presence and maximum diam

180 Two nuclear medicine and 2 genitourinary radiologists independently and in a masked

181 al functions affected by treatment including genitourinary, rectal, and sexual functions.

182 ltifocal or unifocal, leads to a low rate of genitourinary side-effects and an encouraging rate of ea

183 In rhabdomyosarcoma, genitourinary site and embryonal histology confer a rela

184 strains, only one of which was from a female genitourinary source, produced cellular fatty acid and b

185 f sepsis in males (36% vs. 29%, p < .01) and genitourinary sources in females (35% vs. 27%, p < .01).

186 To review the progress of the genitourinary SPORE (Specialized Program of Research Exc

187 has become one of the primary focuses of the genitourinary SPORE in bladder cancer.

188 hogens, organisms, dental, gastrointestinal, genitourinary, streptococcus, enterococcus, staphylococc

189 al and abnormal development of anorectal and genitourinary structures.

190 than 40 years was highest for digestive and genitourinary subsequent primary neoplasms (AER, 5.9 [95

191 orthopedic, 34 vascular, 8 neurologic, and 4 genitourinary surgical procedures, or 29 catheter-based

192 Prespecified outcomes were three genitourinary symptoms (bowel function tenderness, frequ

193 genitalium is considered a leading cause of genitourinary symptoms in men and women, extreme difficu

194 The genitourinary syndrome of menopause has a negative impac

195 Half of postmenopausal women experience genitourinary syndrome of menopause, for which many use

196 is usually requires a suspicion of this rare genitourinary syndrome.

197 and a median elapsed time of 15 years in the genitourinary system (35%), head and neck area (32%), ga

198 formations of the brain, heart, kidneys, and genitourinary system and characterized by a wide range o

199 opy human malformations involving the spine, genitourinary system and distal digestive tract.

200 s approach, we found that development of the genitourinary system and the enteric and autonomic nervo

201 with key roles in normal development of the genitourinary system and tumourigenesis.

202 disorders with respiratory, circulatory and genitourinary system disorders is stronger among African

203 ents the first example of how the developing genitourinary system integrates cues from systemically c

204 n of WT1 and AOC1 proteins in the developing genitourinary system of mice and rats.

205 tes including liver, lung, kidney, bone, and genitourinary system.

206 e in neural crest-derived structures and the genitourinary system.

207 ing congenital and acquired disorders of the genitourinary system.

208 affecting the embryogenesis of the brain and genitourinary systems and including disorders of sex dev

209 We characterized the development of the genitourinary systems in these mice via different method

210 eases of the digestive, musculoskeletal, and genitourinary systems, remain unclear or inconclusive.

211 of gastrointestinal, vascular, pulmonary and genitourinary systems.

212 eases of the digestive, musculoskeletal, and genitourinary systems; many of these associations are im

213 ohn Cunningham virus DNA was found in 75% of genitourinary tissue samples from donors (18 of 24) with

214 es of survival, metastasis, and the ratio of genitourinary tissue weight to body weight were not sign

215 cating) JCV infection mostly predominates in genitourinary tissues but distributes in other tissues a

216 Genitourinary tissues had higher copy numbers than other

217 t, enhances estrogen receptor action in male genitourinary tissues, affects the virilization of the r

218 persist even after bacterial clearance from genitourinary tissues.

219 studies map the fate of cells in developing genitourinary tissues.

220 ality varied by infection sources (19.1% for genitourinary to 43.0% for respiratory; p < 0.001), by n

221 py Oncology Group (RTOG) gastrointestinal or genitourinary toxic effects score up to 12 weeks after r

222 te RT-related grade >= 3 GI (2.5% v 3.9%) or genitourinary toxicity (2.9% v 2.9%).

223 >= 3 gastrointestinal (2% v 3%, P = .33) or genitourinary toxicity (5% v 5%, P = .76) between groups

224 hysician-assessed late gastro intestinal and genitourinary toxicity greater than or equal to grade 2

225 Worst acute RTOG genitourinary toxicity proportions were as follows: grad

226 ts in both arms experienced late grade >/= 3 genitourinary toxicity, and 1% of patients in the high-d

227 eriencing grade 3 and 4 hematologic, GI, and genitourinary toxicity, respectively.

228 4, or 5 (acute or late, gastrointestinal, or genitourinary) toxicity was observed.

229 e intervention group), lung (36%; 58 vs 59), genitourinary tract (12%; 20 vs 19), and breast (10%; 16

230 and pathologic development of the gonads and genitourinary tract and addresses the role of ultrasonog

231 ality of choice for the imaging of pediatric genitourinary tract anomalies.

232 icance of Haemophilus spp. isolated from the genitourinary tract are not well known.

233 requently carried in the gastrointestinal or genitourinary tract as a commensal organism, yet it has

234 There was an excess risk of genitourinary tract cancers among recipients who had exp

235 This case describes a rarely reported non-genitourinary tract clinical isolate of S. pseudoporcinu

236 Six1 and Eya1 genes results in a spectrum of genitourinary tract defects including persistent cloaca

237 ssential roles of the PCM progenitors during genitourinary tract formation.

238 cally confirmed urothelial carcinoma or rare genitourinary tract histologies, Karnofsky performance s

239 c and functional assessment of the pediatric genitourinary tract in a single study without the use of

240 enatal screening and treatment programme for genitourinary tract infections did not reduce the incide

241 ed intervention to screen and treat maternal genitourinary tract infections, with the aim of reducing

242 re we analyzed children born with congenital genitourinary tract masculinization disorders by array-c

243 opriate management and reconstruction of the genitourinary tract may allow for a planned and preempti

244 he relationships between the male and female genitourinary tract microbiomes, and the development of

245 The pathogenesis of an infection of the male genitourinary tract of mice with a human serovar of Chla

246 eudoporcinus was primarily isolated from the genitourinary tract of women but was also associated wit

247 , a recently described organism found in the genitourinary tract of women, was isolated from a thumb

248 Mycoplasma hominis is a commensal genitourinary tract organism that can cause infections o

249 t reduction (46%, P < 0.01) in the weight of genitourinary tract organs in the GSE-fed mice.

250 ment of patients with a variety of suspected genitourinary tract problems, but the procedures are und

251 s article concludes with a listing of BV and genitourinary tract research priorities that were discus

252 enzae type b genogroup strains isolated from genitourinary tract specimens from an adult male veteran

253 lates of the FCG4b group, mainly from female genitourinary tract specimens, as well as the type strai

254 chomatis MoPn results in an infection of the genitourinary tract that closely parallels that describe

255 The urologist involved in the management of genitourinary tract trauma needs to recognize the patter

256 At 30 weeks of age, the average genitourinary tract weights of TRAMP mice were approxima

257 scardovii isolate was from a patient with a genitourinary tract wound infection, two B. longum isola

258 ents adaptive in extraintestinal niches (the genitourinary tract) but detrimental in the main habitat

259 es and patients with rare histologies of the genitourinary tract) were exploratory.

260 al sphincter, separating the rectum from the genitourinary tract, and reconstructing the anus.

261 ndications were cancer affecting the uterus, genitourinary tract, colon, lung or head and neck.

262 tein is normally expressed in the developing genitourinary tract, heart, spleen and adrenal glands an

263 lformations of the appendicular skeleton and genitourinary tract, including digit loss, syndactyly, a

264 s vaginalis, a parasite adapted to the human genitourinary tract, infects globally approximately 250

265 hominis are associated with infection of the genitourinary tract, reproductive failure, and neonatal

266 peptide secreted by epithelial cells in the genitourinary tract.

267 for many common congenital anomalies of the genitourinary tract.

268 ited infection mainly localized to the lower genitourinary tract.

269 is impacted by successful management of the genitourinary tract.

270 n in women, colonizes the gut as well as the genitourinary tract.

271 nostic tool for the imaging of the pediatric genitourinary tract.

272 ganism that can cause infections outside the genitourinary tract.

273 mensal organisms of the gastrointestinal and genitourinary tracts and are commonly used as "probiotic

274 ls that line the digestive, respiratory, and genitourinary tracts form a barrier that many viruses mu

275 mensals, colonizing the gastrointestinal and genitourinary tracts in addition to the oral mucosa.

276 body, particularly the gastrointestinal and genitourinary tracts of healthy individuals.

277 us, GBS) is a commensal of the digestive and genitourinary tracts of humans that emerged as the leadi

278 Colonization of the gastrointestinal and genitourinary tracts of pregnant women with group B Stre

279 enitalium clinical strains isolated from the genitourinary tracts of women attending a sexually trans

280 is of the vasculature, gastrointestinal, and genitourinary tracts.

281 arteries as well as the gastrointestinal and genitourinary tracts.

282 review the 2010/2011 literature on pediatric genitourinary tumors and highlight the most significant

283 review the 2009/2010 literature on pediatric genitourinary tumors and highlight the most significant

284 review the 2008-2009 literature on pediatric genitourinary tumors and highlight the most significant

285 Unlike the more common skin malignancies, genitourinary tumors have a significant impact on both g

286 ng made in understanding the pathogenesis of genitourinary tumors in children, and the prognosis for

287 o be made in the evaluation and treatment of genitourinary tumors in children.

288 l, the prognosis for patients with pediatric genitourinary tumors is favorable.

289 trast, NK cells from patients diagnosed with genitourinary tumors possessed a standard immature signa

290 tumors, such as neuroendocrine carcinoma and genitourinary tumors, are also treated effectively with

291 orary treatments for pediatric patients with genitourinary tumors.

292 orary treatments for pediatric patients with genitourinary tumors.

293 pments in molecular diagnostics in pediatric genitourinary tumors.

294 review the 2007/2008 literature on pediatric genitourinary tumors.

295 e recent (2006/2007) literature on pediatric genitourinary tumors.

296 ew the 2005 and 2006 literature on pediatric genitourinary tumors.

297 s drive risk-stratified therapy in pediatric genitourinary tumors.

298 We review the 2002 literature on pediatric genitourinary tumors.

299 es in prostatic volume, urethral volume, and genitourinary vascularization over time in response to e

300 t decrease in prostate (56%; P < 0.0003) and genitourinary weight (48%; P < 0.008).